National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:HibTITER, HIF-1alpha inhibitor PX-478, high-selenium Brassica juncea, Hiltonol, Hivid
Next:HLA-A*0201-restricted VEGFR1 peptide vaccine, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine, HLA-A*2402-restricted URLC10-KOC1-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov